# J-ALTA (NCT03410108)

> Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

- Drugs tested: brigatinib
- Indication: ALK-positive advanced non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03410108
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Takeda
- Conditions: ALK-positive Advanced NSCLC
- Interventions: Brigatinib
- Enrollment: 104
- Primary outcome: Confirmed Objective Response Rate (ORR) in the Main Cohort of the Refractory Expansion Part
- Primary outcome: 12 Months Progression-Free Survival (PFS) Rate in the Tyrosine Kinase Inhibitor (TKI) Naïve Expansion Cohort

## Indexed commentary on J-ALTA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=j-alta-nct03410108